fgene - 11 - 614726 January 24 , 2021 Time : 15 : 29 # 1 MINI REVIEW published : 28 January 2021 doi : 10 . 3389 / fgene . 2020 . 614726 Edited by : Jianying Zhang , The University of Texas at El Paso , United States Reviewed by : Jitian Li , Luoyang Orthopedic Traumatological Hospital , China Liping Dai , Zhengzhou University , China Paola Cappello , University of Turin , Italy * Correspondence : Carlos A . Casiano ccasiano @ llu . edu ††† Present address : Tino W . Sanchez , National Center for Advancing Translational Sciences , National Institutes of Health , Rockville , MD , United States Specialty section : This article was submitted to Systems Biology , a section of the journal Frontiers in Genetics Received : 06 October 2020 Accepted : 29 December 2020 Published : 28 January 2021 Citation : Almaguel FA , Sanchez TW , Ortiz - Hernandez GL and Casiano CA ( 2021 ) Alpha - Enolase : Emerging Tumor - Associated Antigen , Cancer Biomarker , and Oncotherapeutic Target . Front . Genet . 11 : 614726 . doi : 10 . 3389 / fgene . 2020 . 614726 Alpha - Enolase : Emerging Tumor - Associated Antigen , Cancer Biomarker , and Oncotherapeutic Target Frankis A . Almaguel 1 , 2 , Tino W . Sanchez 1 † , Greisha L . Ortiz - Hernandez 1 and Carlos A . Casiano 1 , 3 * 1 Center for Health Disparities and Molecular Medicine , Department of Basic Sciences , Loma Linda University School of Medicine , Loma Linda , CA , United States , 2 Loma Linda University Cancer Center , Loma Linda , CA , United States , 3 Department of Medicine , Division of Rheumatology , Loma Linda University Health , Loma Linda , CA , United States Alpha - enolase , also known as enolase - 1 ( ENO1 ) , is a glycolytic enzyme that “moonlights” as a plasminogen receptor in the cell surface , particularly in tumors , contributing to cancer cell proliferation , migration , invasion , and metastasis . ENO1 also promotes other oncogenic events , including protein - protein interactions that regulate glycolysis , activation of signaling pathways , and resistance to chemotherapy . ENO1 overexpression has been established in a broad range of human cancers and is often associated with poor prognosis . This increased expression is usually accompanied by the generation of anti - ENO1 autoantibodies in some cancer patients , making this protein a tumor associated antigen . These autoantibodies are common in patients with cancer associated retinopathy , where they exert pathogenic effects , and may be triggered by immunodominant peptides within the ENO1 sequence or by posttranslational modiﬁcations . ENO1 overexpression in multiple cancer types , localization in the tumor cell surface , and demonstrated targetability make this protein a promising cancer biomarker and therapeutic target . This mini - review summarizes our current knowledge of ENO1 functions in cancer and its growing potential as a cancer biomarker and guide for the development of novel anti - tumor treatments . Keywords : alpha - enolase , autoantibodies , cancer biomarker , therapeutic target , ENO1 INTRODUCTION Alpha - enolase ( ENO1 , 47 kD ) has recently emerged as a major driver of tumor metabolism and progression and is considered a rising cancer biomarker and therapeutic target ( Capello et al . , 2011 ; Hsiao et al . , 2013 ; Principe et al . , 2017 ; Cappello et al . , 2018 ) . ENO1 is one of three enolase isoforms encoded by diﬀerent genes : ENO1 , expressed in most human tissues and upregulated in cancer cells ; gamma - enolase ( ENO2 ) , expressed in neuronal cells and neuroendocrine diﬀerentiated tumors ; and beta - enolase ( ENO3 ) , expressed in muscles ( Pancholi , 2001 ; Isgrò et al . , 2015 ; Ji et al . , 2016 ) . These isoforms show high sequence conservation and similar size , and combine to catalyze the dehydration of 2 - phosphoglycerate to phosphoenolpyruvate during glycolysis . In cancer cells , this reaction occurs under both aerobic and anaerobic glycolysis , contributing to the Warburg Eﬀect , Frontiers in Genetics | www . frontiersin . org 1 January 2021 | Volume 11 | Article 614726 fgene - 11 - 614726 January 24 , 2021 Time : 15 : 29 # 2 Almaguel et al . ENO1 , Cancer Biomarker and Target which increases glucose uptake , proliferation , and tumor growth ( Pancholi , 2001 ; Liberti and Locasale , 2016 ; Qian et al . , 2017 ) . Alpha - enolase is overexpressed in multiple human cancer types , contributing to increased glycolysis and tumor growth ( Altenberg and Greulich , 2004 ; Chang et al . , 2006 ; He et al . , 2007 ; Tsai et al . , 2010 ; Capello et al . , 2011 ; Song et al . , 2014 ; Fu et al . , 2015 ; Sun et al . , 2017 , 2019 ; Zhan et al . , 2017 ; Yin et al . , 2018 ; Zhang et al . , 2018 , 2020 ; Cheng et al . , 2019 ; Ji et al . , 2019 ; Qiao et al . , 2019 ; Xu et al . , 2019 ; Chen et al . , 2020 ) . ENO1 overexpression is often associated with anti - ENO1 autoantibody responses and may have prognostic and diagnostic value in certain cancers ( Table 1 ; Adamus et al . , 1998 ; Tomaino et al . , 2011 ; Pranay et al . , 2013 ; Hsiao et al . , 2015 ; Griggio et al . , 2017 ; Zhang et al . , 2020 ) . ENO1 is also localized on the surface of cancer cells where it enhances plasmin formation ( Miles et al . , 1991 ; Redlitz et al . , 1995 ) to promote extracellular matrix degradation , cell migration , invasion , and metastasis ( Hsiao et al . , 2013 ; Didiasova et al . , 2014 ; Principe et al . , 2015 , 2017 ; Zakrzewicz et al . , 2018 ) . These properties make ENO1 a tumor - associated antigen ( TAA ) and promising cancer biomarker and therapeutic target . Below we summarize ENO1’s functions in cancer , growing potential as a cancer biomarker , and rising opportunities for targeting this enzyme for cancer treatment . MULTIFUNCTIONAL ONCOPROTEIN Alpha - enolase mRNA gives rise to an alternative translation product of 37 kD called c - MYC promoter binding protein 1 ( MBP1 ) ( Figure 1A ; Subramanian and Miller , 2000 ) . Although MBP1 does not have glycolytic activity , it regulates the cellular response to altered glucose concentration ( Sedoris et al . , 2007 ) . ENO1 is upregulated by the c - MYC oncoprotein ( Osthus et al . , 2000 ) , and is localized in the cytoplasm and the cell surface , playing multiple roles ( Figure 1B ; Diaz - Ramos et al . , 2012 ; Didiasova et al . , 2019 ) . In contrast , MBP1 is a nuclear protein that represses c - MYC transcription under cellular stress and low glucose conditions , leading to decreased cell proliferation ( Feo et al . , 2000 ; Subramanian and Miller , 2000 ; Sedoris et al . , 2007 ; Maranto et al . , 2015 ) . The ratio of ENO1 / MBP1 expression in cancer cells is regulated by glucose , with c - MYC - driven elevated ENO1 expression under high glucose conditions , and elevated MBP1 expression under low glucose conditions ( Sedoris et al . , 2007 ) . Cancer cells adapt to hypoxia by overexpressing c - MYC , which stimulates glycolysis and cell proliferation via ENO1 upregulation and MBP - 1 downregulation ( Sedoris et al . , 2010 ) . The ENO1 / MBP - 1 ratio inﬂuences cancer aggressiveness , as demonstrated in human breast tumors where overexpression of ENO1 and extracellular matrix metalloproteinases MMP - 2 and MMP - 9 , concomitant with MBP - 1 downregulation , correlates with worse prognosis ( Cancemi et al . , 2019 ) . Alpha - enolase also plays important roles as a plasminogen receptor , component of exosomal vesicles , cytoskeleton reorganizing protein , stabilizer of mitochondrial membrane , and modulator of oncogenic signaling pathways ( Figure 1B ; Diaz - Ramos et al . , 2012 ; Didiasova et al . , 2019 ) . These functions allow overexpressed ENO1 to promote cancer cell proliferation , survival , clonogenicity , epithelial - mesenchymal transition ( EMT ) , chemoresistance , extracellular matrix degradation , migration , invasion , and metastasis . These functions can be inhibited in cancer cells by ENO1 depletion ( Georges et al . , 2011 ; Song et al . , 2014 ; Fu et al . , 2015 ; Zhu et al . , 2015 ; Capello et al . , 2016 ; Principe et al . , 2017 ; Qian et al . , 2017 ; Zhan et al . , 2017 ; Qiao et al . , 2018a , 2019 ; Ji et al . , 2019 ; Sun et al . , 2019 ; Wang et al . , 2019 ; Xu et al . , 2019 ; Santana - Rivera et al . , 2020 ) , or targeting with antibodies ( Hsiao et al . , 2013 ; Principe et al . , 2015 ) , microRNA ( miR ) ( Liu et al . , 2018 ) , or long non - coding RNAs ( lncRNAs ) ( Yu et al . , 2018 ) . ENO1 also regulates oncogenic signaling pathways , including PI3K / Akt ( Fu et al . , 2015 ; Sun et al . , 2019 ; Chen et al . , 2020 ; Zang et al . , 2020 ) , v / β - 3 integrin ( Principe et al . , 2017 ) , β - catenin ( Ji et al . , 2019 ) , transforming growth factor beta ( Xu et al . , 2019 ) , AMPK / mTOR ( Zhan et al . , 2017 ; Dai et al . , 2018 ) , and others ( Huang et al . , 2019 ) . Acting as a plasminogen receptor , ENO1 “moonlights” on the surface of tumor cells to facilitate plasminogen conversion into plasmin ( Miles et al . , 1991 ; Redlitz et al . , 1995 ; Capello et al . , 2011 ; Diaz - Ramos et al . , 2012 ; Ceruti et al . , 2013 ; Hsiao et al . , 2013 ; Didiasova et al . , 2014 , 2019 ) . During inﬂammatory conditions , plasmin activation leads to ﬁbrinolysis and facilitates extracellular matrix degradation , a function linked to ENO1’s ability to promote cancer cell migration , invasion , and metastasis ( Hsiao et al . , 2013 ; Kumari and Malla , 2015 ) . Bacteria and immune cells take advantage of ENO1’s plasminogen receptor functions to facilitate tissue invasion ( Wygrecka et al . , 2009 ; Bergmann et al . , 2013 ) . The plasminogen binding activity of ENO1 has been mapped to the C - terminal peptide 422 KFAGRNFRNPLAK 434 , Miles et al . ( 1991 ) and Redlitz et al . ( 1995 ) , with another putative plasminogen binding site located at 250 FFRSGK 256 ( Figure 1A ; Kang et al . , 2008 ) . ENO1 surface localization is guided by post - translational modiﬁcations ( PTMs ) , particularly methylation of arginine 50 ( Zakrzewicz et al . , 2018 ) . Other PTMs , including citrullination ( Lundberg et al . , 2008 ) , acetylation , and phosphorylation ( Zhou et al . , 2010 ; Capello et al . , 2011 ; Tomaino et al . , 2011 ; Sanchez et al . , 2016 ) , are also likely to inﬂuence ENO1 functions , localization , and immunogenicity ( Didiasova et al . , 2019 ) . ENO1 exteriorization is promoted by lipopolysaccharide ( Zakrzewicz et al . , 2018 ) , calcium inﬂux ( Didiasova et al . , 2015 ) , and interaction with caveolin 1 , annexin 2 , and heat shock protein 70 ( Zakrzewicz et al . , 2014 ; Perconti et al . , 2017 ) . Alpha - enolase interacts in the cell surface with B7 - H3 , an immune co - stimulatory molecule with oncoprotein functions , to promote glycolysis ( Zuo et al . , 2018 ) . It also interacts with granulin A ( GRN - A ) , a 6 kDa peptide derived from progranulin that inhibits ENO1’s ability to promote cancer cell proliferation , migration , and invasion ( Chen et al . , 2017 ) . GRN - A synergizes with cisplatin to induce apoptosis in hepatocellular carcinoma cells ( Qiao et al . , 2018b ) . Overexpressed ENO1 promotes resistance to cisplatin and other anti - tumor drugs in cancer cells by increasing glycolysis and cell proliferation ( Tu et al . , 2010 ; Qian et al . , 2017 ; Qiao et al . , 2018a ; Wang et al . , 2019 ; Santana - Rivera et al . , 2020 ) , interaction with microtubules ( Georges et al . , 2011 ) , and cell adhesion ( Zhu et al . , 2015 ; Principe et al . , 2017 ) . Frontiers in Genetics | www . frontiersin . org 2 January 2021 | Volume 11 | Article 614726 fgene - 11 - 614726 January 24 , 2021 Time : 15 : 29 # 3 Almaguel et al . ENO1 , Cancer Biomarker and Target TABLE 1 | Potential prognostic and diagnostic value of ENO1 expression in tumors and cancer - associated anti - ENO1 autoantibodies . Cancer type Molecule Prognostic / diagnostic value References Bladder ENO1 Prognostic Ji et al . , 2019 Breast ENO1 Prognostic Tu et al . , 2010 ; Cancemi et al . , 2019 Cancer - associated retinopathy Autoantibodies Prognostic ( progressive blinding ) Adamus et al . , 1998 Chronic lymphocytic leukemia Autoantibodies Prognostic Griggio et al . , 2017 Colorectal ENO1 Prognostic Zhan et al . , 2017 Gastric cancer ENO1 Prognostic Qian et al . , 2017 ; Qiao et al . , 2019 ; Sun et al . , 2019 ; Xu et al . , 2019 Glioma ENO1 Prognostic Song et al . , 2014 Head and Neck Both ENO1 and autoantibodies Prognostic Tsai et al . , 2010 ; Pranay et al . , 2013 Liver Both ENO1 and autoantibodies Prognostic / diagnostic Takashima et al . , 2005 ; Hamaguchi et al . , 2008 ; Zhang et al . , 2020 Lung Cancer Both ENO1 and autoantibodies Prognostic / Diagnostic Chang et al . , 2006 ; He et al . , 2007 ; Shih et al . , 2010 ; Hsiao et al . , 2015 ; Dai et al . , 2017 ; Zhang et al . , 2018 ; Zang et al . , 2019 Multiple myeloma ENO1 Prognostic Ray et al . , 2020 Non - Hodgkin’s Lymphoma ENO1 Prognostic Zhu et al . , 2015 Pancreatic cancer Both ENO1 and autoantibodies Prognostic Tomaino et al . , 2011 ; Sun et al . , 2017 ; Yin et al . , 2018 ; Wang et al . , 2019 Alpha - enolase has also been implicated in the regulation of T cell eﬀector functions , including the suppressive functions of induced regulatory T cells ( De Rosa et al . , 2015 ) , T cell activation La Rocca et al . ( 2017 ) , and the diabetogenic functions of islet - speciﬁc CD4 + T cells ( Berry et al . , 2015 ) . Gemta et al . ( 2019 ) recently reported that downregulation of ENO1 activity represses the glycolytic activity of tumor inﬁltrating CD8 + lymphocytes ( CD8 + TILs ) , leading to their functional exhaustion . This impaired ENO1 function is unrelated to its expression , suggesting the involvement of post - transcriptional regulatory mechanisms such as PTMs inﬂuencing ENO1 enzymatic activity or subcellular localization ( Gemta et al . , 2019 ) . TUMOR - ASSOCIATED ANTIGEN The presence of anti - ENO1 autoantibodies is well documented in autoimmune diseases such as rheumatoid arthritis ( RA ) and autoimmune retinopathy ( Adamus , 2017 ) . In RA , these autoantibodies recognize an immunodominant citrullinated peptide within the ENO1 N - terminus ( Lundberg et al . , 2008 ) , and are clinical diagnostic biomarkers . Alpha - enolase autoantibodies are also present in cancer patients , often associated with cancer - associated retinopathy ( CAR ) ( Adamus , 2017 ) . Unlike in RA , ENO1 autoantibodies from CAR patients do not speciﬁcally target citrullinated peptides but rather recognize several epitopes , including an immunodominant N - terminal domain peptide , 56 RYMGKGVS 63 , and a C - terminal peptide implicated in plasminogen binding , 421 AKFAGRNF 428 ( Adamus et al . , 1998 ) . CAR - linked ENO1 autoantibodies promote retinopathy by inducing retinal cell apoptosis , leading to retinal dysfunction or degeneration ( Adamus , 2018 ; Adamus et al . , 2020 ) . In vitro treatment of retinal cells with an anti - ENO1 monoclonal antibody signiﬁcantly impaired glycolysis , reduced ATP production , and induced apoptosis ( Magrys et al . , 2007 ) . ENO1 autoantibodies from patients with autoimmune retinopathy also target retinal ganglion cells and induce apoptosis in rats ( Ren and Adamus , 2004 ) . Further , the survival of retinal cells treated with ENO1 autoantibodies from patients with autoimmune retinopathy and CAR was impaired compared to retinal cells exposed to sera from healthy controls ( Adamus et al . , 1998 ) . While ENO1 autoantibodies are known to trigger pathological eﬀects through their internalization by retinal cells ( Ren and Adamus , 2004 ) , it cannot be ruled out that they also directly target cell surface ENO1 , leading to glycolysis impairment and apoptosis . The study of ENO1 autoantibodies in CAR has uncovered a potential unintended consequence - i . e . , antibody - induced retinal apoptosis - that requires careful consideration as ENO1 - based cancer immunotherapies are developed . Alpha - enolase autoantibodies are associated with either improved or poor tumor patient outcomes in diﬀerent cancer types , suggesting a context - dependent clinical signiﬁcance ( Table 1 ; Shih et al . , 2010 ; Tomaino et al . , 2011 ; Pranay et al . , 2013 ; Hsiao et al . , 2015 ; Griggio et al . , 2017 ) . While these autoantibodies may occur in cancer patients independent of CAR , a recent study showed that vision loss and anti - retinal autoantibodies occur in at least 20 diﬀerent human cancers , with ENO1 being the most frequent target of these antibodies ( Adamus et al . , 2020 ) . Autoantibodies to other glycolytic enzymes have also been detected in CAR patients ( Adamus et al . , 2020 ) , suggesting that they are induced by immune presentation of peptides from overexpressed metabolic proteins released from tumor cells ( Adamus et al . , 2020 ) . ENO1 autoantibodies have been included in TAA panels for cancer immunodiagnosis . For instance , Zang et al . ( 2019 ) examined a panel of four cancer biomarkers ( carcinoembryonic antigen , cancer antigen 125 , Annexin A1 autoantibodies , and ENO1 autoantibodies ) for lung cancer detection that yielded high speciﬁcity , sensitivity , and diagnostic accuracy . Dai et al . ( 2017 ) Frontiers in Genetics | www . frontiersin . org 3 January 2021 | Volume 11 | Article 614726 fgene - 11 - 614726 January 24 , 2021 Time : 15 : 29 # 4 Almaguel et al . ENO1 , Cancer Biomarker and Target FIGURE 1 | Structure and functions of human ENO1 . ( A ) Schematic representation of domain structure of ENO1 and its alternative translation variant c - MYC promoter binding protein 1 ( MBP1 ) . Several lysine residues ( K256 , K422 , and K434 ) have been implicated in the plasminogen binding functions of ENO1 , whereas K343 has been implicated in its catalytic activity , required for the conversion of 2 - phosphoglycerate to phosphoenolpyruvate during glycolysis . Citrullination of arginines 9 ( R9 ) and 15 ( R15 ) generates an immunodominant peptide ( residues 5 – 22 ) that is targeted by autoantibodies in patients with rheumatoid arthritis . Methylation of arginine 50 ( R50 ) has been implicated in ENO1 externalization . R50 is also part of an immunodominant epitope recognized by autoantibodies from patients with cancer associated retinopathy ( CAR ) . Another CAR epitope is located within the plasminogen binding domain . Phosphorylated serine 419 ( S419 ) within the plasminogen binding domain is recognized of ENO1 autoantibodies in pancreatic cancer patients . While MBP1 shares the catalytic and plasminogen binding domains of ENO1 , it lacks these functions due to its exclusive nuclear localization . MPB1 residues 1 – 139 ( ENO1 96 – 236 ) comprise its DNA binding domain , required for binding to the c - MYC gene promoter , which results in repression of promoter activity and downregulation of c - MYC protein expression . ( B ) Schematic representation of the cellular functions of ENO1 and MBP1 . MBP1 localizes primarily in the cell nucleus where it represses the c - MYC gene promoter , whose activity is essential for ENO1 upregulation . ENO1 is primarily localized in the cytoplasm , where it functions in glycolysis , promoting mitochondrial stability and cytoskeleton reorganization , and regulating oncogenic signaling pathways . This protein is also localized on the cell surface , where it acts as a plasminogen receptor and interacting partner of various proteins to regulate glycolysis , as well as cancer cell migration , invasion , and metastasis . ENO1 can also be secreted from cells as a component of exosomal vesicles . also reported that combining ENO1 autoantibodies with carcinoembryonic antigen and cytokeratin 19 fragment in a diagnostic panel increased diagnostic sensitivity for non - small cell lung cancer . Another study detected ENO1 autoantibodies at higher frequencies in patients with early stage lung cancer compared to late stage patients ( Zhang et al . , 2018 ) . Post - translational modiﬁcations contribute to the generation of ENO1 autoantibodies , as evidenced by the observation Frontiers in Genetics | www . frontiersin . org 4 January 2021 | Volume 11 | Article 614726 fgene - 11 - 614726 January 24 , 2021 Time : 15 : 29 # 5 Almaguel et al . ENO1 , Cancer Biomarker and Target that patients with pancreatic ductal adenocarcinoma ( PDA ) produce antibodies that speciﬁcally target epitopes containing phosphorylated serine 419 within the plasminogen binding domain of ENO1 ( Figure 1 ) , and correlate with improved outcome in patients receiving chemotherapy , suggesting a protective role ( Tomaino et al . , 2011 ) . It is not clear if , like in RA , citrullination triggers ENO1 autoantibodies in cancer patients , although citrullinated ENO1 was reported to elicit anti - tumor CD4 + T responses in murine tumor xenografts and in ovarian cancer patients ( Cook et al . , 2018 ; Brentville et al . , 2020 ) . Our group and others identiﬁed citrullinated ENO1 in cancer cells ( Jiang et al . , 2013 ; Sanchez et al . , 2016 ) , suggesting that this PTM could potentially trigger ENO1 autoantibodies in cancer patients . We reported that ENO1 autoantibodies occur at higher frequency in prostate cancer ( PCa ) patients compared to controls , showing racial diﬀerences in reactivity ( Sanchez et al . , 2016 ) . While autoantibodies from European American ( EA ) PCa patients reacted strongly with human recombinant ENO1 by ELISA but weakly by immunoblotting against endogenous ENO1 from PCa cells , autoantibodies from African American ( AA ) patients showed the opposite pattern . ENO1 autoantibodies from AA patients also displayed diﬀerential reactivity against endogenous ENO1 in a panel of PCa cell lines , reacting strongly with ENO1 in metastatic PCa cell lines by immunoblotting , whereas autoantibodies from EA patients reacted uniformly against this protein across the panel . Intriguingly , ENO1 autoantibodies from AA patients lost immunoreactivity in docetaxel - resistant cells , while autoantibodies from EA patients retained this reactivity . Proteomics analysis revealed diﬀerences in PTMs ( e . g . , acetylation , methylation , phosphorylation , and citrullination ) within endogenous ENO1 between chemosensitive and chemoresistant PCa cells , suggesting that the observed racial diﬀerences in ENO1 autoantibody reactivity in these cell types might be inﬂuenced by PTMs . In addition to ovarian cancer ( Brentville et al . , 2020 ) , T cell responses targeting ENO1 have also been reported in patients with PDA . ENO1 - speciﬁc CD8 + T cell responses were detected in 8 out of 12 PDA patients with circulating anti - ENO1 IgG autoantibodies , whereas patients without these autoantibodies lacked these responses , suggesting an integrated humoral and cellular anti - ENO1 response ( Cappello et al . , 2009 ) . A later study reported that phosphorylated ENO1 also triggers CD4 + T cell responses in PDA patients ( Capello et al . , 2015 ) . CANCER BIOMARKER AND THERAPEUTIC TARGET The need for new cancer - speciﬁc targets that can act as beacons to localize tumors with high eﬃciency is a key feature of a robust biomarker . As mentioned above , growing evidence suggests that ENO1 is upregulated in a broad range of human tumors , making it a candidate cancer biomarker . ENO1 localization on the surface of cancer cells also provides an excellent opportunity to develop small molecules with high aﬃnity to this protein , which enables its direct targeting in the tumor surface for diagnostic imaging and therapeutics . The diagnostic and prognostic value of ENO1 overexpression has been conﬁrmed in several tumors ( Table 1 ) . For example , in breast cancer , enhanced ENO1 expression correlated with greater tumor size , poor nodal status , and a shorter disease - free interval ( Tu et al . , 2010 ) . Patients with lung cancer overexpressing ENO1 also showed poor clinical outcomes , with shorter overall and progression - free survival , compared to low expressing patients ( Chang et al . , 2006 ; Hsiao et al . , 2013 ) . ENO1 overexpression in hepatocellular carcinoma increased with tumor de - diﬀerentiation and correlated positively with venous invasion ( Takashima et al . , 2005 ; Hamaguchi et al . , 2008 ) . These characteristics position ENO1 as a selective biomarker able to identify aggressive tumor types with high accuracy . Alpha - enolase has several key characteristics of an ideal cancer biomarker : ( 1 ) localization in the cell surface where it can be targeted for imaging and treatment ; ( 2 ) overexpression in cancer cells with low expression in normal tissues ; and ( 3 ) overexpression correlating with prognosis and clinical outcomes . Thus , ENO1 can be envisioned as an excellent biomarker to guide patient management and alter disease timeline . Ultimately , ENO1 surface imaging could potentially be used to screen for occult cancers . This information could then be translated to improve prognosis and management of patients diagnosed with cancer by monitoring disease state , detecting recurrence and progression , or assessing response to therapy . Alpha - enolase has a potent three punch combination to advance cancer progression : ( 1 ) promotes tumor glycolysis , ( 2 ) activates cancer signaling pathways , and ( 3 ) drives tumor migration , invasion , and metastasis . These unique characteristics make ENO1 a strong candidate to deliver targeted therapies to tumors overexpressing this protein , particularly those tumors expressing surface ENO1 . For instance , molecular imaging of tumors guided by ENO1 - speciﬁc small molecule probes could open the door to new strategies to target this protein in tumors , leading to early interventions and improved patient outcomes . Several reports have already provided pre - clinical data supporting ENO1 therapeutic targeting . As mentioned above , ENO1 depletion attenuates glycolysis , cell proliferation , EMT , migration , and invasion , and metastasis in several cancer types ( Fu et al . , 2015 ; Capello et al . , 2016 ; Principe et al . , 2017 ; Zhan et al . , 2017 ; Ji et al . , 2019 ; Sun et al . , 2019 ) . Targeting of ENO1 in combination with chemotherapy may be beneﬁcial in patients with drug resistant cancers given , as mentioned earlier , its emerging role in chemoresistance . There is a major need for small molecule inhibitors of ENO1 . A promising inhibitor , ENOblock , has been used to target ENO1 in various disease contexts ( Jung et al . , 2013 ; Cho et al . , 2017 , 2019 ; Haque et al . , 2017 ; Polcyn et al . , 2020 ) but its speciﬁcity was disputed ( Satani et al . , 2016 ) . Another ENO1 inhibitor was recently reported to enhance anti - multiple myeloma ( MM ) immunity in combination with immunotherapy in pre - clinical models ( Ray et al . , 2020 ) . In addition , a novel nanoparticle - delivered peptide targeting ENO1 in combination with doxorubicin demonstrated strong antitumor activity in pre - clinical models of PCa ( Wang et al . , 2018 ) . The study of immune responses to ENO1 has sparked the development of novel immunotherapeutic strategies . Frontiers in Genetics | www . frontiersin . org 5 January 2021 | Volume 11 | Article 614726 fgene - 11 - 614726 January 24 , 2021 Time : 15 : 29 # 6 Almaguel et al . ENO1 , Cancer Biomarker and Target For instance , treatment of lung cancer cells with anti - ENO1 monoclonal antibodies in vitro suppressed cell - associated plasminogen and matrix metalloproteinase activation , collagen and gelatin degradation , and cell invasion ( Hsiao et al . , 2013 ) . Interestingly , adoptive transfer of these antibodies to mice resulted in their accumulation in subcutaneous tumors and inhibition of lung and bone metastases . Principe et al . ( 2015 ) reported that in vitro and in vivo blockade of ENO1 with anti - human ENO1 monoclonal antibodies reduced PDA cell migration and invasion . Further , administration of adeno - associated virus ( AAV ) encoding an anti - ENO1 monoclonal antibody led to a reduction of lung metastasis in mouse PDA xenografts ( Principe et al . , 2015 ) . The same group developed an ENO1 DNA vaccine that signiﬁcantly inhibited , although did not eradicate , tumor growth in a mouse PDA model , suggesting that the eﬀectiveness of this vaccine could be ampliﬁed in the context of combinatorial therapies ( Cappello et al . , 2013 , 2018 ) . Recently , Mandili et al . ( 2020 ) demonstrated that treatment of PDA mice with combined gemcitabine chemotherapy and ENO1 DNA vaccination induced a strong CD4 + T cell antitumor activity that impaired tumor progression , compared with mice that received vaccine or gemcitabine alone . CONCLUSION Alpha - enolase promotes cellular functions associated with tumor aggressiveness , including increased glycolysis , activation of oncogenic signaling pathways , chemoresistance , and cell proliferation , migration , invasion , and metastasis . Therefore , ENO1 can be considered an oncoprotein critical for maintaining several “hallmarks of cancer” ( Hanahan and Weinberg , 2011 ) , particularly sustained proliferative signaling , deregulated energy metabolism , apoptosis resistance , and activation of invasion and metastasis . ENO1 overexpression in a broad range of human cancers and targetability make it an attractive cancer biomarker candidate and therapeutic target . Its localization in the tumor surface , key metabolic functions , and ability to promote tumor aggressive properties could be exploited for the development of novel comprehensive cancer care modalities that combine ENO1 surface imaging with targeted therapeutic interventions . AUTHOR CONTRIBUTIONS GLO - H designed and prepared the ﬁgures and crosschecked the references for accuracy . CAC designed the overall organization of the manuscript and approved the ﬁnal version . All authors contributed to the literature review and the writing and ﬁnal editing of the manuscript . FUNDING Research on ENO1 and other tumor - associated antigens in the authors’ laboratories was funded in part by National Institutes of Health ( NIH ) grants P20MD006988 - Project 2 and R21CA226654 - 01A1 to CAC , Loma Linda University ( LLU ) Center for Health Disparities and Molecular Medicine , LLU School of Medicine , and LLU Cancer Center . GLO - H was supported by NIH grant R25GM060507 and the LLU - NIH Initiative for Maximizing Student Development ( IMSD ) graduate training program . REFERENCES Adamus , G . ( 2017 ) . Impact of autoantibodies against glycolytic enzymes on pathogenicity of autoimmune retinopathy and other autoimmune disorders . Front . Immunol . 8 : 505 . doi : 10 . 3389 / ﬁmmu . 2017 . 00505 Adamus , G . ( 2018 ) . Are anti - retinal autoantibodies a cause or a consequence of retinal degeneration in autoimmune retinopathies ? Front . Immunol . 9 : 765 . doi : 10 . 3389 / ﬁmmu . 2018 . 00765 Adamus , G . , Amundson , D . , Seigel , G . M . , andMachnicki , M . ( 1998 ) . Anti - enolase - alpha autoantibodies in cancer - associated retinopathy : epitope mapping and cytotoxicity on retinal cells . J . Autoimmun . 11 , 671 – 677 . doi : 10 . 1006 / jaut . 1998 . 0239 Adamus , G . , Champaigne , R . , andYang , S . ( 2020 ) . Occurrenceofmajoranti - retinal autoantibodies associated with paraneoplastic autoimmune retinopathy . Clin . Immunol . 210 : 108317 . doi : 10 . 1016 / j . clim . 2019 . 108317 Altenberg , B . , and Greulich , K . O . ( 2004 ) . Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes . Genomics 2004 , 1014 – 1020 . doi : 10 . 1016 / j . ygeno . 2004 . 08 . 010 Bergmann , S . , Schoenen , H . , and Hammerschmidt , S . ( 2013 ) . The interaction between bacterial enolase and plasminogen promotes adherence of Streptococcus pneumoniae to epithelial and endothelial cells . Int . J . Med . Microbiol . 303 , 452 – 462 . doi : 10 . 1016 / j . ijmm . 2013 . 06 . 002 Berry , G . J . , Frielle , C . , Luu , T . , Salzberg , A . C . , Rainbow , D . B . , Wicker , L . S . , et al . ( 2015 ) . Genome - wide transcriptional analyses of islet - speciﬁc CD4 + T cells identify Idd9 genes controlling diabetogenic T cell function . J . Immunol . 194 , 2654 – 2663 . doi : 10 . 4049 / jimmunol . 1401288 Brentville , V . A . , Metheringham , R . L . , Daniels , I . , Atabani , S . , Symonds , P . , Cook , K . W . , et al . ( 2020 ) . Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4 - mediated anti - tumor responses . J . Immunother . Cancer . 8 , e000560 . doi : 10 . 1136 / jitc - 2020 - 000560 Cancemi , P . , Buttacavoli , M . , Roz , E . , and Feo , S . ( 2019 ) . Expression of alpha - Enolase ( ENO1 ) , Myc promoter - binding protein - 1 ( MBP - 1 ) and matrix metalloproteinases ( MMP - 2 and MMP - 9 ) reﬂect the nature and aggressiveness of breast tumors . Int . J . Mol . Sci . 20 , 3952 . doi : 10 . 3390 / ijms20163952 Capello , M . , Caorsi , C . , Bogantes Hernandez , P . J . , Dametto , E . , Bertinetto , F . E . , Magistroni , P . , et al . ( 2015 ) . Phosphorylated alpha - enolase induces autoantibodies in HLA - DR8 pancreatic cancer patients and triggers HLA - DR8 restrictedT - cellactivation . Immunol . Lett . 167 , 11 – 16 . doi : 10 . 1016 / j . imlet . 2015 . 06 . 008 Capello , M . , Ferri - Borgogno , S . , Cappello , P . , and Novelli , F . ( 2011 ) . α - Enolase : a promising therapeutic and diagnostic tumor target . FEBS J . 278 , 1064 – 1074 . doi : 10 . 1111 / j . 1742 - 4658 . 2011 . 08025 . x Capello , M . , Ferri - Borgogno , S . , Riganti , C . , Chattaragada , M . S . , Principe , M . , Roux , C . , et al . ( 2016 ) . Targeting the Warburg eﬀect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest . Oncotarget 7 , 5598 – 5612 . doi : 10 . 18632 / oncotarget . 6798 Cappello , P . , Curcio , C . , Mandili , G . , Roux , C . , Bulfamante , S . , and Novelli , F . ( 2018 ) . Next generation immunotherapy for pancreatic cancer : DNA vaccination is seeking new combo partners . Cancers 10 , 51 . doi : 10 . 3390 / cancers10020051 Cappello , P . , Rolla , S . , Chiarle , R . , Principe , M . , Cavallo , F . , Perconti , G . , et al . ( 2013 ) . Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer . Gastroenterology 144 , 1098 – 1106 . doi : 10 . 1053 / j . gastro . 2013 . 01 . 020 Cappello , P . , Tomaino , B . , Chiarle , R . , Ceruti , P . , Novarino , A . , Castagnoli , C . , etal . ( 2009 ) . An integrated humoral and cellular response is elicited in pancreatic Frontiers in Genetics | www . frontiersin . org 6 January 2021 | Volume 11 | Article 614726 fgene - 11 - 614726 January 24 , 2021 Time : 15 : 29 # 7 Almaguel et al . ENO1 , Cancer Biomarker and Target cancer by alpha - enolase , a novel pancreatic ductal adenocarcinoma - associated antigen . Int . J . Cancer 125 , 639 – 648 . doi : 10 . 1002 / ijc . 24355 Ceruti , P . , Principe , M . , Capello , M . , Cappello , P . , and Novelli , F . ( 2013 ) . Three are better than one : plasminogen receptors as cancer theranostic targets . Exp . Hematol . Oncol . 2 , 12 . doi : 10 . 1186 / 2162 - 3619 - 2 - 12 Chang , G . C . , Liu , K . J . , Hsieh , C . L . , Hu , T . S . , Charoenfuprasert , S . , Liu , H . K . , et al . ( 2006 ) . Identiﬁcation of alpha - enolase as an autoantigen in lung cancer : its overexpression is associated with clinical outcomes . Clin . Cancer Res . 12 , 5746 – 5754 . doi : 10 . 1158 / 1078 - 0432 . CCR - 06 - 0324 Chen , J . M . , Chiu , S . C . , Chen , K . C . , Huang , Y . J . , Liao , Y . A . , and Yu , C . R . ( 2020 ) . Enolase 1 diﬀerentially contributes to cell transformation in lung cancer but not in esophageal cancer . Oncol . Lett . 19 , 3189 – 3196 . doi : 10 . 3892 / ol . 2020 . 11427 Chen , X . , Xu , H . , Wu , N . , Liu , X . , Qiao , G . , Su , S . , et al . ( 2017 ) . Interaction between granulin A and enolase 1 attenuates the migration and invasion of human hepatoma cells . Oncotarget 8 , 30305 – 30316 . doi : 10 . 18632 / oncotarget . 16328 Cheng , Z . , Shao , X . , Xu , M . , Zhou , C . , and Wang , J . ( 2019 ) . ENO1 acts as a prognostic biomarker candidate and promotes tumor growth and migration ability through the regulation of Rab1A in colorectal cancer . Cancer Manag . Res . 11 , 9969 – 9978 . doi : 10 . 2147 / CMAR . S226429 Cho , H . , Lee , J . H . , Um , J . , Kim , S . , Kim , Y . , Kim , W . H . , et al . ( 2019 ) . ENOblock inhibits the pathology of diet - induced obesity . Sci . Rep . 9 , 493 . doi : 10 . 1038 / s41598 - 018 - 36715 - 3 Cho , H . , Um , J . , Lee , J . H . , Kim , W . H . , Kang , W . S . , Kim , S . H . , et al . ( 2017 ) . ENOblock , a unique small molecule inhibitor of the non - glycolytic functions of enolase , alleviates the symptoms of type 2 diabetes . Sci . Rep . 7 , 44186 . doi : 10 . 1038 / srep44186 Cook , K . , Daniels , I . , Symonds , P . , Pitt , T . , Gijon , M . , Xue , W . , et al . ( 2018 ) . Citrullinated α - enolase is an eﬀective target for anti - cancer immunity . Oncoimmunology 7 , e1390642 . Dai , J . , Zhou , Q . , Chen , J . , Rexius - Hall , M . L . , Rehman , J . , and Zhou , G . ( 2018 ) . Alpha - enolase regulates the malignant phenotype of pulmonary artery smooth muscle cells via the AMPK - Akt pathway . Nat . Commun . 9 , 3850 . doi : 10 . 1038 / s41467 - 018 - 06376 - x Dai , L . , Qu , Y . , Li , J . , Wang , X . , Wang , K . , Wang , P . , et al . ( 2017 ) . Serological proteome analysis approach - based identiﬁcation of ENO1 as a tumor - associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21 - 1 in the detection of non - small cell lung cancer . Oncotarget 8 , 36664 – 36673 . doi : 10 . 18632 / oncotarget . 17067 DeRosa , V . , Galgani , M . , Porcellini , A . , Colamatteo , A . , Santopaolo , M . , Zuchegna , C . , et al . ( 2015 ) . Glycolysis controls the induction of human regulatory T cells bymodulatingtheexpressionofFOXP3exon2splicingvariants . Nat . Immunol . 16 , 1174 – 1184 . doi : 10 . 1038 / ni . 3269 Diaz - Ramos , A . , Roig - Borrellas , A . , Garcia - Melero , A . , and Lopez - Alemany , R . ( 2012 ) . Alpha - Enolase , amultifunctionalprotein : itsroleonpathophysiological situations . J . Biomed . Biotechnol . 2012 , 156795 . doi : 10 . 1155 / 2012 / 156795 Didiasova , M . , Schaefer , L . , and Wygrecka , M . ( 2019 ) . When place matters : shuttling of Enolase - 1 across cellular compartments . Front . Cell . Dev . Biol . 7 : 61 . doi : 10 . 3389 / fcell . 2019 . 00061 Didiasova , M . , Wujak , L . , Wygrecka , M . , and Zakrzewicz , D . ( 2014 ) . From plasminogen to plasmin : role of plasminogen receptors in human cancer . Int . J . Mol . Sci . 15 , 21229 – 21252 . doi : 10 . 3390 / ijms151121229 Didiasova , M . , Zakrzewicz , D . , Magdolen , V . , Nagaraj , C . , Bálint , Z . , Rohde , M . , et al . ( 2015 ) . M . STIM1 / ORAI1 - mediated Ca2 + inﬂux regulates Enolase - 1 exteriorization . J . Biol . Chem . 290 , 11983 – 11999 . doi : 10 . 1074 / jbc . M114 . 598425 Feo , S . , Arcuri , D . , Piddini , E . , Passantino , R . , andGiallongo , A . ( 2000 ) . ENO1gene product binds to the c - myc promoter and acts as a transcriptional repressor : relationship with Myc promoter - binding protein 1 ( MBP - 1 ) . FEBS Lett . 473 , 47 – 52 . doi : 10 . 1016 / s0014 - 5793 ( 00 ) 01494 - 0 Fu , Q . F . , Liu , Y . , Fan , Y . , Hua , S . N . , Qu , H . Y . , Dong , S . W . , et al . ( 2015 ) . Alpha - enolase promotes cell glycolysis , growth , migration , and invasion in non - small cell lung cancer through FAK - mediated PI3K / AKT pathway . J . Hematol . Oncol . 8 , 22 . doi : 10 . 1186 / s13045 - 015 - 0117 - 5 Gemta , L . F . , Siska , P . J . , Nelson , M . E . , Gao , X . , Liu , X . , Locasale , J . W . , etal . ( 2019 ) . Impaired enolase 1 glycolytic activity restrains eﬀector functions of tumor - inﬁltrating CD8 + T cells . Sci . Immunol . 4 , eaa9520 . doi : 10 . 1126 / sciimmunol . aap9520 Georges , E . , Bonneau , A . M . , and Prinos , P . ( 2011 ) . RNAi - mediated knockdown of α - enolase increases the sensitivity of tumor cells to antitubulin chemotherapeutics . Int . J . Biochem . Mol . Biol . 2 , 303 – 308 . Griggio , V . , Mandili , G . , Vitale , C . , Capello , M . , Macor , P . , Serra , S . , et al . ( 2017 ) . Humoral immune responses toward tumor - derived antigens in previously untreated patients with chronic lymphocytic leukemia . Oncotarget 8 , 3274 – 3288 . doi : 10 . 18632 / oncotarget . 13712 Hamaguchi , T . , Iizuka , N . , Tsunedomi , R . , Hamamoto , Y . , Miyamoto , T . , Iida , M . , et al . ( 2008 ) . Glycolysis module activated by hypoxia - inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma . Int . J . Oncol . 33 , 725 – 731 . Hanahan , D . , andWeinberg , R . A . ( 2011 ) . Hallmarksofcancer : thenextgeneration . Cell 144 , 646 – 674 . doi : 10 . 1016 / j . cell . 2011 . 02 . 013 Haque , A . , Capone , M . , Matzelle , D . , Cox , A . , and Banik , N . L . ( 2017 ) . Targeting enolase in reducing secondary damage in acute spinal cord injury in rats . Neurochem . Res . 42 , 2777 – 2787 . doi : 10 . 1007 / s11064 - 017 - 2291 - z He , P . , Naka , T . , Serada , S . , Fujimoto , M . , Tanaka , T . , Hashimoto , S . , et al . ( 2007 ) . Proteomics - based identiﬁcation of alpha - enolase as a tumor antigen in non - small lung cancer . Cancer Sci . 98 , 1234 – 1240 . doi : 10 . 1111 / j . 1349 - 7006 . 2007 . 00509 . x Hsiao , K . C . , Shih , N . Y . , Chu , P . Y . , Hung , Y . M . , Liao , J . Y . , Chou , S . W . , et al . ( 2015 ) . Anti - α - enolase is a prognostic marker in postoperative lung cancer patients . Oncotarget 6 , 35073 – 35086 . doi : 10 . 18632 / oncotarget . 5316 Hsiao , K . C . , Shih , N . Y . , Fang , H . L . , Huang , T . S . , Kuo , C . C . , Chu , P . Y . , et al . ( 2013 ) . Surface α - enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target . PLoS One 8 : e69354 . doi : 10 . 1371 / journal . pone . 0069354 Huang , Z . , Lin , B . , Pan , H . , Du , J . , He , R . , Zhang , S . , et al . ( 2019 ) . Gene expression proﬁleanalysisofENO1knockdowningastriccancercelllineMGC - 803 . Oncol . Lett . 17 , 3881 – 3889 . doi : 10 . 3892 / ol . 2019 . 10053 Isgrò , M . A . , Bottoni , P . , and Scatena , R . ( 2015 ) . Neuron - speciﬁc enolase as a biomarker : biochemical and clinical aspects . Adv . Exp . Med . Biol . 867 , 125 – 143 . doi : 10 . 1007 / 978 - 94 - 017 - 7215 - 0 _ 9 Ji , H . , Wang , J . , Guo , J . , Li , Y . , Lian , S . , Guo , W . , et al . ( 2016 ) . Progress in the biologicalfunctionofalpha - enolase . Anim . Nutr . 2 , 12 – 17 . doi : 10 . 1016 / j . aninu . 2016 . 02 . 005 Ji , M . , Wang , Z . , Chen , J . , Gu , L . , Chen , M . , Ding , Y . , et al . ( 2019 ) . Up - regulated ENO1 promotes the bladder cancer cell growth and proliferation via regulating β - catenin . Biosci . Rep . 39 , BSR20190503 . doi : 10 . 1042 / BSR20190503 Jiang , Z . , Cui , Y . , Wang , L . , Zhao , Y . , Yan , S . , and Chang , X . ( 2013 ) . Investigating citrullinated proteins in tumour cell lines . World J . Surg . Oncol . 11 , 260 . doi : 10 . 1186 / 1477 - 7819 - 11 - 260 Jung , D . W . , Kim , W . H . , Park , S . H . , Lee , J . , Kim , J . , Su , D . , et al . ( 2013 ) . A unique small molecule inhibitor of enolase clariﬁes its role in fundamental biological processes . ACS Chem . Biol . 8 , 1271 – 1282 . doi : 10 . 1021 / cb300687k Kang , H . J . , Jung , S . K . , Kim , S . J . , and Chung , S . J . ( 2008 ) . Structure of human alpha - enolase ( hENO1 ) , a multifunctional glycolytic enzyme . Acta Crystallogr . D Biol . Crystallogr . 64 , 651 – 657 . doi : 10 . 1107 / S0907444908008561 Kumari , S . , and Malla , R . ( 2015 ) . New insight on the role of plasminogen receptor in cancer progression . Cancer Growth Metastasis 8 , 35 – 42 . doi : 10 . 4137 / CGM . S27335 La Rocca , C . , Carbone , F . , De Rosa , V . , Colamatteo , A . , Galgani , M . , Perna , F . , et al . ( 2017 ) . Immunometabolic proﬁling of T cells from patients with relapsing - remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration . Metabolism 77 , 39 – 46 . doi : 10 . 1016 / j . metabol . 2017 . 08 . 011 Liberti , M . V . , and Locasale , J . W . ( 2016 ) . Metabolism : a new layer of glycolysis . Nat . Chem . Biol . 12 , 577 – 578 . doi : 10 . 1038 / nchembio . 2133 Liu , Y . , Li , H . , Liu , Y . , and Zhu , Z . ( 2018 ) . MiR - 22 - 3p targeting alpha - enolase 1 regulates the proliferation of retinoblastoma cells . Biomed . Pharmacother . 105 , 805 – 812 . doi : 10 . 1016 / j . biopha . 2018 . 06 . 038 Lundberg , K . , Kinloch , A . , Fisher , B . A . , Wegner , N . , Wait , R . , Charles , P . , et al . ( 2008 ) . Antibodies to citrullinated alpha - enolase peptide 1 are speciﬁc for rheumatoid arthritis and cross - react with bacterial enolase . Arthritis Rheum . 58 , 3009 – 3019 . doi : 10 . 1002 / art . 23936 Magrys , A . , Anekonda , T . , Ren , G . , and Adamus , G . ( 2007 ) . The role of anti - alpha - enolase autoantibodies in pathogenicity of autoimmune - mediated retinopathy . J . Clin . Immunol . 27 , 181 – 192 . doi : 10 . 1007 / s10875 - 006 - 9065 - 8 Frontiers in Genetics | www . frontiersin . org 7 January 2021 | Volume 11 | Article 614726 fgene - 11 - 614726 January 24 , 2021 Time : 15 : 29 # 8 Almaguel et al . ENO1 , Cancer Biomarker and Target Mandili , G . , Curcio , C . , Bulfamante , S . , Follia , L . , Ferrero , G . , Mazza , E . , et al . ( 2020 ) . In pancreatic cancer , chemotherapy increases antitumor responses to tumor - associated antigens and potentiates DNA vaccination . J . Immunother . Cancer 8 , e001071 . doi : 10 . 1136 / jitc - 2020 - 001071 Maranto , C . , Perconti , G . , Contino , F . , Rubino , P . , Feo , S . , andGiallongo , A . ( 2015 ) . Cellular stress induces cap - independent alpha - enolase / MBP - 1 translation . FEBS Lett . 589 , 2110 – 2116 . doi : 10 . 1016 / j . febslet . 2015 . 06 . 030 Miles , L . A . , Dahlberg , C . M . , Plescia , J . , Felez , J . , Kato , K . , and Plow , E . F . ( 1991 ) . Role of cell - surface lysines in plasminogen binding to cells : identiﬁcation of alpha - enolase as a candidate plasminogen receptor . Biochemistry 30 , 1682 – 1691 . doi : 10 . 1021 / bi00220a034 Osthus , R . C . , Shim , H . , Kim , S . , Li , Q . , Reddy , R . , Mukherjee , M . , et al . ( 2000 ) . Deregulation of glucose transporter 1 and glycolytic gene expression by c - Myc . J . Biol . Chem . 275 , 21797 – 21800 . doi : 10 . 1074 / jbc . C000023200 Pancholi , V . ( 2001 ) . Multifunctional alpha - enolase : its role in diseases . Cell Mol . Life Sci . 58 , 902 – 920 . doi : 10 . 1007 / pl00000910 Perconti , G . , Maranto , C . , Romancino , D . P . , Rubino , P . , Feo , S . , Bongiovanni , A . , et al . ( 2017 ) . Pro - invasive stimuli and the interacting protein Hsp70 favour the route of alpha - enolase to the cell surface . Sci . Rep . 7 , 3841 . doi : 10 . 1038 / s41598 - 017 - 04185 - 8 Polcyn , R . , Capone , M . , Matzelle , D . , Hossain , A . , Chandran , R . , Banik , N . L . , et al . ( 2020 ) . Enolase inhibition alters metabolic hormones and inﬂammatory factors to promote neuroprotection in spinal cord injury . Neurochem . Int . 139 , 104788 . doi : 10 . 1016 / j . neuint . 2020 . 104788 Pranay , A . , Shukla , S . , Kannan , S . , Malgundkar , S . A . , Govekar , R . B . , Patil , A . , et al . ( 2013 ) . Prognostic utility of autoantibodies to α - enolase and Hsp70 for cancer ofthegingivo - buccalcomplexusingimmunoproteomics . ProteomicsClin . Appl . 7 , 392 – 402 . doi : 10 . 1002 / prca . 201200081 Principe , M . , Borgoni , S . , Cascione , M . , Chattaragada , M . S . , Ferri - Borgogno , S . , Capello , M . , et al . ( 2017 ) . Alpha - enolase ( ENO1 ) controls alpha v / beta 3 integrin expression and regulates pancreatic cancer adhesion , invasion , and metastasis . J . Hematol . Oncol . 10 , 16 . doi : 10 . 1186 / s13045 - 016 - 0385 - 8 Principe , M . , Ceruti , P . , Shih , N . Y . , Chattaragada , M . S . , Rolla , S . , Conti , L . , et al . ( 2015 ) . Targeting of surface alpha - enolase inhibits the invasiveness of pancreatic cancer cells . Oncotarget 6 , 11098 – 11113 . doi : 10 . 18632 / oncotarget . 3572 Qian , X . , Xu , W . , Xu , J . , Shi , Q . , Li , J . , Weng , Y . , et al . ( 2017 ) . Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer . Oncotarget 8 , 47691 – 47708 . doi : 10 . 18632 / oncotarget . 17868 Qiao , G . , Xu , H . , Li , C . , Li , X . , Farooqi , A . A . , Zhao , Y . , et al . ( 2018b ) . Granulin A synergizes with cisplatin to inhibit the growth of human hepatocellular carcinoma . Int . J . Mol . Sci . 19 , 3060 . doi : 10 . 3390 / ijms19103060 Qiao , H . , Wang , Y . , Zhu , B . , Jiang , L . , Yuan , W . , Zhou , Y . , et al . ( 2019 ) . Enolase1 overexpression regulates the growth of gastric cancer cells and predicts poor survival . J . Cell . Biochem . 120 , 18714 – 18723 . doi : 10 . 1002 / jcb . 29179 Qiao , H . , Wang , Y . F . , Yuan , W . Z . , Zhu , B . D . , Jiang , L . , and Guan , Q . L . ( 2018a ) . Silencing of ENO1 by shRNA inhibits the proliferation of gastric cancer cells . Technol . Cancer Res . Treat . 17 , 1533033818784411 . doi : 10 . 1177 / 1533033818784411 Ray , A . , Song , Y . , Du , T . , Chauhan , D . , and Anderson , K . C . ( 2020 ) . Preclinical validation of Alpha - Enolase ( ENO1 ) as a novel immunometabolic target in multiple myeloma . Oncogene 39 , 2786 – 2796 . doi : 10 . 1038 / s41388 - 020 - 1172 - 0 Redlitz , A . , Fowler , B . J . , Plow , E . F . , and Miles , L . A . ( 1995 ) . The role of an enolase - relatedmoleculeinplasminogenbindingtocells . Eur . J . Biochem . 227 , 407 – 415 . doi : 10 . 1111 / j . 1432 - 1033 . 1995 . tb20403 . x Ren , G . , and Adamus , G . ( 2004 ) . Cellular targets of anti - alpha - enolase autoantibodies of patients with autoimmune retinopathy . J . Autoimmun . 23 , 161 – 167 . doi : 10 . 1016 / j . jaut . 2004 . 06 . 003 Sanchez , T . W . , Zhang , G . , Li , J . , Dai , L . , Mirshahidi , S . , Wall , N . R . , et al . ( 2016 ) . ImmunoseroproteomicproﬁlinginAfricanamericanmenwithprostate cancer : evidence for an autoantibody response to glycolysis and plasminogen - associated proteins . Mol . Cell . Proteomics . 15 , 3564 – 3580 . doi : 10 . 1074 / mcp . M116 . 060244 Santana - Rivera , Y . , Rabelo - Fernández , R . J . , Quiñones - Díaz , B . I . , Grafals - Ruíz , N . , Santiago - Sánchez , G . , Lozada - Delgado , E . L . , et al . ( 2020 ) . Reduced expression of enolase - 1 correlates with high intracellular glucose levels and increased senescence in cisplatin - resistant ovarian cancer cells . Am . J . Transl . Res . 12 , 1275 – 1292 . Satani , N . , Lin , Y . H . , Hammoudi , N . , Raghavan , S . , Georgiou , D . K . , and Muller , F . L . ( 2016 ) . ENOblock does not inhibit the activity of the glycolytic enzyme enolase . PLoS One 11 : e0168739 . doi : 10 . 1371 / journal . pone . 0168739 Sedoris , K . C . , Thomas , S . D . , and Miller , D . M . ( 2007 ) . c - myc promoter binding protein regulates the cellular response to an altered glucose concentration . Biochemistry 46 , 8659 – 8668 . doi : 10 . 1021 / bi7003558 Sedoris , K . C . , Thomas , S . D . , andMiller , D . M . ( 2010 ) . Hypoxiainducesdiﬀerential translationofenolase / MBP - 1 . BMCCancer 10 : 157 . doi : 10 . 1186 / 1471 - 2407 - 10 - 157 Shih , N . Y . , Lai , H . L . , Chang , G . C . , Lin , H . C . , Wu , Y . C . , Liu , J . M . , et al . ( 2010 ) . Anti - alpha - enolase autoantibodies are down - regulated in advanced cancer patients . Jpn . J . Clin . Oncol . 40 , 663 – 669 . doi : 10 . 1093 / jjco / hyq028 Song , Y . , Luo , Q . , Long , H . , Hu , Z . , Que , T . , Zhang , X . , et al . ( 2014 ) . Alpha - enolase as a potential cancer prognostic marker promotes cell growth , migration , and invasion in glioma . Mol . Cancer 13 , 65 . doi : 10 . 1186 / 1476 - 4598 - 13 - 65 Subramanian , A . , and Miller , D . M . ( 2000 ) . Structural analysis of alpha - enolase . Mapping the functional domains involved in down - regulation of the c - myc protooncogene . J . Biol . Chem . 275 , 5958 – 5965 . doi : 10 . 1074 / jbc . 275 . 8 . 5958 Sun , L . , Guo , C . , Cao , J . , Burnett , J . , Yang , Z . , Ran , Y . , et al . ( 2017 ) . Over - expression of alpha - Enolase as a prognostic biomarker in patients with pancreatic cancer . Int . J . Med . Sci . 14 , 655 – 661 . doi : 10 . 7150 / ijms . 18736 Sun , L . , Lu , T . , Tian , K . , Zhou , D . , Yuan , J . , Wang , X . , et al . ( 2019 ) . Alpha - enolase promotes gastric cancer cell proliferation and metastasis via regulating AKT signaling pathway . Eur . J Pharmacol . 845 , 8 – 15 . doi : 10 . 1016 / j . ejphar . 2018 . 12 . 035 Takashima , M . , Kuramitsu , Y . , Yokoyama , Y . , Iizuka , N . , Fujimoto , M . , Nishisaka , T . , et al . ( 2005 ) . Overexpression of alpha enolase in hepatitis C virus - related hepatocellularcarcinoma : associationwithtumorprogressionasdeterminedby proteomic analysis . Proteomics 5 , 1686 – 1692 . doi : 10 . 1002 / pmic . 200401022 Tomaino , B . , Cappello , P . , Capello , M . , Fredolini , C . , Sperduti , I . , Migliorini , P . , et al . ( 2011 ) . Circulating autoantibodies to phosphorylated alpha - enolase are a hallmark of pancreatic cancer . J . Proteome Res . 10 , 105 – 112 . doi : 10 . 1021 / pr100213b Tsai , S . T . , Chien , I . H . , Shen , W . H . , Kuo , Y . Z . , Jin , Y . T . , Wong , T . Y . , et al . ( 2010 ) . ENO1 , a potential prognostic head and neck cancer marker , promotes transformation partly via chemokine CCL20 induction . Eur . J . Cancer 46 , 1712 – 1723 . doi : 10 . 1016 / j . ejca . 2010 . 03 . 018 Tu , S . H . , Chang , C . C . , Chen , C . S . , Tam , K . W . , Wang , Y . J . , Lee , C . H . , etal . ( 2010 ) . Increasedexpressionofenolasealphainhumanbreastcancerconferstamoxifenresistanceinhumanbreastcancercells . Breast Cancer Res . Treat . 121 , 539 – 553 . doi : 10 . 1007 / s10549 - 009 - 0492 - 0 Wang , L . , Bi , R . , Yin , H . , Liu , H . , and Li , L . ( 2019 ) . ENO1 silencing impaires hypoxia - induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells . Am . J . Transl . Res . 11 , 4470 – 4480 . Wang , L . , Qu , M . , Huang , S . , Fu , Y . , Yang , L . , He , S . , et al . ( 2018 ) . A novel α - enolase - targeted drug delivery system for high eﬃcacy prostate cancer therapy . Nanoscale 10 , 13673 – 13683 . doi : 10 . 1039 / c8nr03297a Wygrecka , M . , Marsh , L . M . , Morty , R . E . , Henneke , I . , Guenther , A . , Lohmeyer , J . , et al . ( 2009 ) . Enolase - 1 promotes plasminogen - mediated recruitment of monocytes to the acutely inﬂamed lung . Blood 113 , 5588 – 5598 . doi : 10 . 1182 / blood - 2008 - 08 - 170837 Xu , X . , Chen , B . , Zhu , S . , Zhang , J . , He , X . , Cao , G . , et al . ( 2019 ) . Hyperglycemia promotes Snail - induced epithelial - mesenchymal transition of gastric cancer via activating ENO1 expression . Cancer Cell Int . 19 , 344 . doi : 10 . 1186 / s12935 - 019 - 1075 - 8 Yin , H . , Wang , L . , andLiu , H . L . ( 2018 ) . ENO1overexpressioninpancreaticcancer patients and its clinical and diagnostic signiﬁcance . Gastroenterol . Res . Pract . 2018 , 3842198 . doi : 10 . 1155 / 2018 / 3842198 Yu , S . , Li , N . , Huang , Z . , Chen , R . , Yi , P . , Kang , R . , et al . ( 2018 ) . A novel lncRNA , TCONS _ 00006195 , represseshepatocellularcarcinomaprogressionby inhibiting enzymatic activity of ENO1 . Cell Death Dis . 9 , 1184 . doi : 10 . 1038 / s41419 - 018 - 1231 - 4 Zakrzewicz , D . , Didiasova , M . , Krüger , M . , Giaimo , B . D . , Borggrefe , T . , Mieth , M . , et al . ( 2018 ) . Protein arginine methyltransferase 5 mediates enolase - 1 cell surface traﬃcking in human lung adenocarcinoma cells . Biochim . Biophys . Acta Mol . Basis Dis . 1864 , 1816 – 1827 . doi : 10 . 1016 / j . bbadis . 2018 . 02 . 021 Zakrzewicz , D . , Didiasova , M . , Zakrzewicz , A . , Hocke , A . C . , Uhle , F . , Markart , P . , et al . ( 2014 ) . The interaction of enolase - 1 with caveolae - associated proteins Frontiers in Genetics | www . frontiersin . org 8 January 2021 | Volume 11 | Article 614726 fgene - 11 - 614726 January 24 , 2021 Time : 15 : 29 # 9 Almaguel et al . ENO1 , Cancer Biomarker and Target regulates its subcellular localization . Biochem . J . 460 , 295 – 307 . doi : 10 . 1042 / BJ20130945 Zang , H . Y . , Gong , L . G . , Li , S . Y . , and Hao , J . G . ( 2020 ) . Inhibition of α - enolase aﬀects the biological activity of breast cancer cells by attenuating PI3K / Akt signaling pathway . Eur . Rev . Med . Pharmacol . Sci . 24 , 249 – 257 . doi : 10 . 26355 / eurrev _ 202001 _ 19917 Zang , R . , Li , Y . , Jin , R . , Wang , X . , Lei , Y . , Che , Y . , et al . ( 2019 ) . Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection . Oncoimmunology 8 , e1625689 . doi : 10 . 1080 / 2162402X . 2019 . 1625689 Zhan , P . , Zhao , S . , Yan , H . , Yin , C . , Xiao , Y . , Wang , Y . , et al . ( 2017 ) . α - enolase promotes tumorigenesis and metastasis via regulating AMPK / mTOR pathway in colorectal cancer . Mol . Carcinog . 56 , 1427 – 1437 . doi : 10 . 1002 / mc . 22603 Zhang , L . , Lu , T . , Yang , Y . , and Hu , L . ( 2020 ) . α - enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis . Oncol . Lett . 20 , 152 . doi : 10 . 3892 / ol . 2020 . 12003 Zhang , L . , Wang , H . , andDong , X . ( 2018 ) . Diagnosticvalueof α - enolaseexpression and serum α - enolase autoantibody levels in lung cancer . J . Bras . Pneumol . 44 , 18 – 23 . doi : 10 . 1590 / S1806 - 37562016000000241 Zhou , W . , Capello , M . , Fredolini , C . , Piemonti , L . , Liotta , L . A . , Novelli , F . , et al . ( 2010 ) . Mass spectrometry analysis of the post - translational modiﬁcations of alpha - enolase from pancreatic ductal adenocarcinoma cells . J . Proteome Res . 9 , 2929 – 2936 . doi : 10 . 1021 / pr901109w Zhu , X . , Miao , X . , Wu , Y . , Li , C . , Guo , Y . , Liu , Y . , et al . ( 2015 ) . ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance ( CAM - DR ) in Non - Hodgkin’s Lymphomas . Exp . Cell Res . 335 , 216 – 223 . doi : 10 . 1016 / j . yexcr . 2015 . 05 . 020 Zuo , J . , Wang , B . , Long , M . , Gao , Z . , Zhang , Z . , Wang , H . , et al . ( 2018 ) . The type 1 transmembraneglycoproteinB7 - H3interactswiththeglycolyticenzymeENO1 to promote malignancy and glycolysis in HeLa cells . FEBS Lett . 592 , 2476 – 2488 . doi : 10 . 1002 / 1873 - 3468 . 13164 Conﬂict of Interest : The authors declare that the research was conducted in the absence of any commercial or ﬁnancial relationships that could be construed as a potential conﬂict of interest . Copyright © 2021 Almaguel , Sanchez , Ortiz - Hernandez and Casiano . This is an open - access article distributed under the terms of the Creative Commons Attribution License ( CC BY ) . The use , distribution or reproduction in other forums is permitted , provided the original author ( s ) and the copyright owner ( s ) are credited and that the original publication in this journal is cited , in accordance with accepted academic practice . No use , distribution or reproduction is permitted which does not comply with these terms . Frontiers in Genetics | www . frontiersin . org 9 January 2021 | Volume 11 | Article 614726